By Chase Doyle  / April 25, 2022  / 2022 Society of Surgical Oncology International Conference on Surgical Care

Is Neoadjuvant Pembrolizumab Underused in the Treatment of Early-Stage Triple-Negative Breast Cancer?

Neoadjuvant pembrolizumab has been approved in combination with chemotherapy for high-risk, early-stage, triple-negative breast cancer, but not all patients with node-positive disease have been able t...